Publications

Detailed Information

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

DC Field Value Language
dc.contributor.authorOu, Sai-Hong Ignatius-
dc.contributor.authorKwak, Eunice L.-
dc.contributor.authorSiwak-Tapp, Christina-
dc.contributor.authorDy, Joni-
dc.contributor.authorBergethon, Kristin-
dc.contributor.authorClark, Jeffrey W.-
dc.contributor.authorCamidge, D. Ross-
dc.contributor.authorSolomon, Benjamin J.-
dc.contributor.authorMaki, Robert G.-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorKim, Dong-Wan-
dc.contributor.authorChristensen, James-
dc.contributor.authorTan, Weiwei-
dc.contributor.authorWilner, Keith D.-
dc.contributor.authorSalgia, Ravi-
dc.contributor.authorIafrate, A. John-
dc.date.accessioned2020-04-27T11:35:14Z-
dc.date.available2020-04-27T11:35:14Z-
dc.date.created2020-04-08-
dc.date.issued2011-05-
dc.identifier.citationJournal of Thoracic Oncology, Vol.6 No.5, pp.942-946-
dc.identifier.issn1556-0864-
dc.identifier.other95271-
dc.identifier.urihttps://hdl.handle.net/10371/165514-
dc.description.abstractCrizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.-
dc.language영어-
dc.publisherElsevier Inc.-
dc.titleActivity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1097/JTO.0b013e31821528d3-
dc.citation.journaltitleJournal of Thoracic Oncology-
dc.identifier.wosid000289554100015-
dc.identifier.scopusid2-s2.0-79955458487-
dc.citation.endpage946-
dc.citation.number5-
dc.citation.startpage942-
dc.citation.volume6-
dc.identifier.sci000289554100015-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
dc.contributor.affiliatedAuthorKim, Dong-Wan-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusGENE COPY NUMBER-
dc.subject.keywordPlusRESISTANCE-
dc.subject.keywordPlusMUTATIONS-
dc.subject.keywordPlusGEFITINIB-
dc.subject.keywordPlusERLOTINIB-
dc.subject.keywordPlusSURVIVAL-
dc.subject.keywordPlusTUMORS-
dc.subject.keywordPlusLEADS-
dc.subject.keywordAuthorNon-small cell lung cancer-
dc.subject.keywordAuthorDe novo MET amplification NSCLC-
dc.subject.keywordAuthor18(F)-FDG PET/CT-
dc.subject.keywordAuthorCrizotinib (PF02341066)-
dc.subject.keywordAuthorMET polysomy-
dc.subject.keywordAuthorAnaplastic lymphoma kinase (ALK) re-arranged NSCLC-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share